Your session is about to expire
← Back to Search
Other
Excipient Impact on Drug Absorption
Phase < 1
Recruiting
Led By Kathleen M Giacomini, Ph.D.
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male and females between the ages of 18-64 years old, inclusive
Be between 18 and 65 years old
Must not have
Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal surgery
Subjects taking any drugs, especially known OATP2B1 substrates (aliskiren, atenolol, celiprolol, fexofenadine, rosuvastatin and ticlopidine, etc.) except birth control hormonal medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-48 hours
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if adding sodium lauryl sulfate (SLS) to fexofenadine changes how well the drug works. It looks at people taking fexofenadine and checks drug levels in the blood and stool to see if SLS makes a difference. SLS has been shown to help various substances get into the body better.
Who is the study for?
Healthy adults aged 18-64, willing to avoid certain fruit juices and supplements, can join this trial. They must not be extremely obese, allergic to the drug or its components, have low hemoglobin levels, be pregnant/breastfeeding without birth control use, or have liver/kidney/heart diseases.
What is being tested?
The study is testing how a common non-drug ingredient called sodium lauryl sulfate (SLS) affects the absorption of Fexofenadine Hydrochloride. Participants will take the drug with varying amounts of SLS to see if there's any difference in how well their body absorbs it.
What are the potential side effects?
While specific side effects are not listed for this trial scenario since it involves healthy volunteers and a commonly used medication component (SLS), typical reactions might include digestive discomfort or allergic responses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 64 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had gastrointestinal issues or surgery.
Select...
I am not on medication that affects drug transport in my body, except for birth control.
Select...
My liver, kidney, or heart function is not impaired.
Select...
My BMI is over 35.
Select...
I do not speak English.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0-48 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-48 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Area under the plasma concentration versus time curve (AUC) of Fexofenadine
Maximum Plasma Concentration (Cmax) of Fexofenadine
Secondary study objectives
Fexofenadine stool amount
Sodium lauryl sulfate plasma concentration
Sodium lauryl sulfate stool amount
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Fexofenadine without SLSExperimental Treatment1 Intervention
Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
Group II: Fexofenadine and 30 mg SLSExperimental Treatment1 Intervention
Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
Group III: Fexofenadine and 3 mg SLSExperimental Treatment1 Intervention
Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Excipients, such as sodium lauryl sulfate (SLS), play a crucial role in drug absorption by modifying the drug's solubility and permeability. SLS, a surfactant, can enhance the absorption of drugs by reducing surface tension and increasing the wettability of the drug particles, thereby improving their dissolution rate.
This is particularly important for drugs with poor water solubility, as it can significantly impact their bioavailability and therapeutic efficacy. Understanding the role of excipients like SLS is essential for optimizing drug formulations to ensure consistent and effective drug delivery for patients.
Comparison of dissolution profiles and serum concentrations of two lamotrigine tablet formulations.Enhancement of heparin and heparin disaccharide absorption by the Phytolacca americana saponins.Targeted delivery of salicylic acid from acne treatment products into and through skin: role of solution and ingredient properties and relationships to irritation.
Comparison of dissolution profiles and serum concentrations of two lamotrigine tablet formulations.Enhancement of heparin and heparin disaccharide absorption by the Phytolacca americana saponins.Targeted delivery of salicylic acid from acne treatment products into and through skin: role of solution and ingredient properties and relationships to irritation.
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,938 Total Patients Enrolled
Food and Drug Administration (FDA)FED
181 Previous Clinical Trials
1,548,637 Total Patients Enrolled
Kathleen M Giacomini, Ph.D.Principal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
20 Total Patients Enrolled
Deanna Kroetz, Ph.D.Principal InvestigatorUniversity of California, San Francisco
Katherine Yang, PharmD, MPHPrincipal InvestigatorUniversity of California, San Francisco